home / stock / oxbdf / oxbdf quote
Last: | $3.79 |
---|---|
Change Percent: | 0.0% |
Open: | $3.79 |
Close: | $3.79 |
High: | $3.79 |
Low: | $3.79 |
Volume: | 100 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.79 | $3.79 | $3.79 | $3.79 | $3.79 | 100 | 05-02-2024 |
$2.91 | $2.85 | $2.91 | $2.91 | $2.85 | 1,100 | 04-26-2024 |
$2.82 | $2.82 | $2.82 | $2.82 | $2.82 | 400 | 04-25-2024 |
$2.72 | $2.72 | $2.72 | $2.72 | $2.72 | 900 | 04-23-2024 |
$2.62 | $2.62 | $2.62 | $2.62 | $2.62 | 1,630 | 04-22-2024 |
$2.615 | $2.615 | $2.615 | $2.615 | $2.615 | 600 | 04-11-2024 |
$2.625 | $2.625 | $2.625 | $2.625 | $2.625 | 300 | 04-05-2024 |
$2.44 | $2.65 | $2.44 | $2.65 | $2.44 | 400 | 04-03-2024 |
$2.43 | $0 | $2.43 | $0 | $0 | 75 | 03-28-2024 |
$2.43 | $2.43 | $2.43 | $2.43 | $2.43 | 200 | 03-26-2024 |
$2.48 | $2.48 | $2.48 | $2.48 | $2.48 | 101 | 03-25-2024 |
$2.46 | $2.46 | $2.46 | $2.46 | $2.46 | 2,000 | 03-21-2024 |
$2.4 | $2.4 | $2.4 | $2.4 | $2.4 | 825 | 03-18-2024 |
$2.44 | $2.44 | $2.44 | $2.44 | $2.44 | 300 | 03-15-2024 |
$2.568 | $2.568 | $2.568 | $2.568 | $2.568 | 340 | 03-13-2024 |
$2.72 | $0 | $2.72 | $0 | $0 | 50 | 03-12-2024 |
$2.72 | $2.51 | $2.72 | $2.72 | $2.51 | 834 | 03-07-2024 |
$2.4815 | $2.4815 | $2.4815 | $2.4815 | $2.4815 | 1,260 | 03-06-2024 |
$2.5 | $2.5 | $2.5 | $2.5 | $2.5 | 185 | 03-05-2024 |
$2.17 | $2.17 | $2.17 | $2.17 | $2.17 | 100 | 03-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Oxford Biomedica (OXBDF) is expected to report for Q4 2023 Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q4 2024 Express (02Z0:MU) is expected to report $-8.99 for Q4 2024 Express Inc. - Ord...
Oxford Biomedica (OXBDF) is expected to report for Q4 2023
LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emer...